| 询价 | |
| M00547 | |
|
|
|
|
|
|
|
|
|
| Product Description | Recombinant CHO-K1 cells stably overexpress human vasoactive intestinal peptide receptor 2 (VPAC2) and luciferase gene which can be translated under the control of cAMP response element (CRE). This product contains high levels of G protein Gαs to couple with the VPAC2 receptor in downstream signaling pathway (cAMP/PKA). |
| Culture Properties | Adherent. |
| Stability | Stability: Stable through more than 16 passages with no significant changes in assay performance or expression profile. |
| Size | Two vials of frozen cells (>1×106 per vial in 1 mL) |
| Storage | Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received. |
| Culture Medium | Ham’s F-12K (Kaighn’s), 10% FBS, 100 μg/ml Hygromycin B (Cat. No. 10687010, Life Technologies), 200 μg/ml Zeocin (Cat. No. R250-01, Life Technologies) |
| Complete Growth Medium | Ham’s F-12K (Kaighn’s), 10% FBS. |
| Freeze Medium-DATA | 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Life Technologies), 10% DMSO (Cat. No. D2650, Sigma). |
Figure 1. VIP-induced luciferase expression in CHO-K1/CRE-Luc/VPAC2 cells. After stimulation by VIP for 6 hours, the cells are determined with Fire-Lumi™ Luciferase Assay System (Cat. No. L00877C-100, Genscript) and the relative luminescence units (RLU) were recorded by plate reader (Pherastar, BMG). The RLU were plotted against the log of the cumulative doses of VIP (Mean ± SEM, n = 3). The EC50 of VIP on cells was 0.50 nM.
»
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
